News
Christine Hummel joins Leap as SVP of Manufacturer and Specialty Network Partnerships
Leap is growing its leadership team. We're excited to welcome Christine Hummel as Senior Vice President of Manufacturer and Specialty Network Partnerships.
Christine brings more than two decades of healthcare leadership experience spanning pharmaceutical manufacturing, pharmacy services, and specialty distribution, most recently in executive roles at Sanofi, CVS Health, and McKesson. In her new role, she'll lead Leap's strategy and partnerships across pharmaceutical manufacturers and specialty care networks, helping expand access to specialty therapies through more transparent, coordinated care.
"What drew me to Leap is the opportunity to rethink one of the most complex and costly parts of the patient journey through a transparent, clinically focused model," said Christine. "I'm excited to build partnerships that make specialty therapies easier to access while creating value across the healthcare ecosystem."
Her appointment reflects Leap's continued investment in building strong relationships across the specialty drug ecosystem, as the company works with manufacturers, providers, and industry partners to improve access, streamline care, and create value for everyone involved, from employers to patients.
Read the full announcement on Business Wire.
About Leap
Leap makes specialty medicine more affordable and easier to access. Available in all 50 states, Leap supports more than 200 therapies for cancer, multiple sclerosis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, migraine, immunodeficiency disorders, and other complex or chronic illnesses. Every patient is paired with a dedicated, licensed Care Guide, and Leap has earned an industry-leading patient Net Promoter Score of 92.
More insights
Want to increase member participation in a specialty medicine solution? Reducing or waiving cost share is a good start.
One employee at a self-funded employer received Gammagard infusions twice a month for a rare autoimm...
6 specialty medicine trends for 2027 and what they mean for benefits leaders
If it feels like specialty medicine is changing faster than your benefits strategy can keep up, that...
Evaluate healthcare point solutions with 5 simple questions
If every healthcare point solution delivered the return in its sales deck, employer health costs wou...
Leap expands specialty infusion network with WeInfuse collaboration
Leap is expanding its employer specialty infusion network through a new collaboration with WeInfuse,...
Infusion vs. injection: Breaking down the basics of these two specialty therapies
In 1995, there were about 30 specialty drugs on the market. Today, there are nearly 1,000, and rough...
Let's blow up the buy-and-bill drug model: How it works and what it costs employers
Twice a year, a member with multiple sclerosis (MS) sits down for an Ocrevus infusion. The drug is t...
The real cost of MS infusion therapy and how a better member experience can bring down costs
For two years, Maria drove two hours each way for her multiple sclerosis (MS) treatment. Every appoi...
The emerging oncology biosimilars market and how employers can prepare.
A member who starts Keytruda today will likely organize the next two years of their life around it. ...
Is home infusion safe for immunoglobulin therapy? What patients should know
Whether you've just been prescribed immunoglobulin (Ig) therapy, or you've been getting it at a clin...
The market is moving faster than most infusion strategies can keep up with
Hospital systems have been acquiring independent physician practices at a rapid pace for close to tw...